ulipristal acetate has been researched along with Adenomyosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Donnez, J; Donnez, O | 1 |
| Brun, JL; Capmas, P; Fernandez, H; Koskas, M; Legendre, G; Merviel, P | 1 |
| Agostini, A; Calderon, L; Grob-Vaillant, A; Mancini, J; Netter, A; Siles, P; Vidal, V | 1 |
| Chodankar, RR; Critchley, HOD; Murray, A; Nicol, M; Whitaker, LHR; Williams, ARW | 1 |
| Camilli, S; Conway, F; Exacoustos, C; Martire, FG; Morosetti, G; Piccione, E; Sorrenti, G; Zupi, E | 1 |
| Han, SJ; Hong, YH; Jee, BC; Kim, SK; Lee, D | 1 |
| Bastianelli, C; Benagiano, G; Brosens, I; Farris, M | 1 |
1 review(s) available for ulipristal acetate and Adenomyosis
| Article | Year |
|---|---|
Selective progesterone receptor modulators: an update.
Topics: Adenomyosis; Animals; Clinical Trials as Topic; Contraception, Postcoital; Contraceptive Agents, Female; Contraceptives, Postcoital; Endometriosis; Estrenes; Female; Hormone Antagonists; Humans; Leiomyoma; Levonorgestrel; Mifepristone; Norpregnadienes; Oximes; Receptors, Progesterone; Uterine Neoplasms | 2014 |
1 trial(s) available for ulipristal acetate and Adenomyosis
| Article | Year |
|---|---|
Ulipristal acetate use in adenomyosis: A randomized controlled trial.
Topics: Adenomyosis; Adult; Amenorrhea; Contraceptive Agents, Hormonal; Double-Blind Method; Female; Fertility Preservation; Humans; Menstruation Disturbances; Norpregnadienes; Pilot Projects; Quality of Life | 2021 |
5 other study(ies) available for ulipristal acetate and Adenomyosis
| Article | Year |
|---|---|
Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis.
Topics: Adenomyosis; Adult; Disease Progression; Drug Substitution; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Norpregnadienes; Remission Induction; Severity of Illness Index; Treatment Failure; Uterus | 2020 |
Progression of adenomyosis magnetic resonance imaging features under ulipristal acetate for symptomatic fibroids.
Topics: Adenomyosis; Adult; Contraceptive Agents, Female; Disease Progression; Female; Humans; Leiomyoma; Magnetic Resonance Imaging; Norpregnadienes; Pilot Projects; Prospective Studies | 2021 |
The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Topics: Adenomyosis; Adult; Cross-Sectional Studies; Endometrium; Female; Gene Expression Regulation; Humans; Leiomyoma; Ligands; Menorrhagia; Middle Aged; Norpregnadienes; Receptors, Progesterone; RNA, Messenger; Time Factors; Treatment Outcome; Uterine Neoplasms | 2021 |
Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids.
Topics: Adenomyosis; Diagnostic Errors; Disease Progression; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Ultrasonography; Uterine Neoplasms; Uterus | 2019 |
Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis.
Topics: Adenomyosis; Adult; Contraceptive Agents, Female; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leiomyoma; Middle Aged; Norpregnadienes; Receptors, Progesterone; Uterine Neoplasms; Young Adult | 2019 |